Biocon’s moment of reckoning

With biosimilars in the limelight, Kiran Mazumdar-Shaw’s company is poised to become one of India’s most important drug makers

Last October, in New York, Kiran Mazumdar-Shaw did what she does best—make the news.

Talking at the UNAIDS Health Innovation Exchange held at the United Nations General Assembly, the founder of Biocon Ltd made an offer to make available human insulin at $0.10 per day to low- and middle-income countries, less than half the current prices. It was no mean offer, given that these countries accounted for 80% of the diabetes burden.

Around the same time, in the Bengaluru headquarters of her company, managers were hard at work trying to find additional funds for several other things she had set …


T Surendar

Surendar helps lead the newsroom at The Morning Context as executive editor. Over the years, Surendar has worked in industries from pharmaceuticals to diamonds, as well as a stint as an equity analyst. In his long career as a business journalist, he has led teams at The Times of India, India Today and Fortune India. He was part of the founding team at Forbes India and interned at and published in The Times, London.

Executive Editor